Article
Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
European journal of clinical pharmacology - 1 Jan 1994
Botsch S, Heinkele G, Meese C O, Eichelbaum M, Kroemer H K
Abstract excerpt
Metabolism of the antiarrhythmic, propafenone, cosegregates with the sparteine/debrisoquine polymorphism. Patients devoid of CYP2D6 activity have a higher incidence of adverse effects than those with normal enzyme function. In this paper we present a method for rapid assignment of CYP2D6 phenotype using urinary excretion of intact glucuronides of propafenone (PPFG). After establishing an HPLC assay, urinary...
Topics
- Aged
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 Enzyme System
- Female
- Glucuronates
- Humans
- Male
- Middle Aged
- Mixed Function Oxygenases
- Phenotype
- Propafenone